Posted on March 6, 2019 by Sitemaster
As many readers will remember, Prostvac is an active immunotherapeutic vaccine that — some years ago — had shown promising results in a randomized Phase II clinical trial. … READ MORE …
Filed under: Uncategorized | Tagged: clinical, Prostvac, trial | 1 Comment »
Posted on September 15, 2017 by Sitemaster
Apparently, late yesterday, Barvarian Nordic announced that Prostvac has failed to show efficacy in the Phase III PROSPECT trial of the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). Click here for Barvarian Nordic’s media release.
Filed under: Drugs in development, Management, Treatment | Tagged: Barvarian, mCRPC, Nordic, PROSPECT, Prostvac, trial | 4 Comments »
Posted on June 16, 2017 by Sitemaster
Barvarian Nordic has again delayed (slightly) when they expect to have the initial results of the Phase III clinical trial of Prostvac in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development | Tagged: mCRPC, outcome, Prostvac, result, trial | Leave a comment »
Posted on January 5, 2017 by Sitemaster
According to Barvarian Nordic, the key results of the Phase III clinical trial of the immunologic agent Prostvac (rilimogene galvacirepvec/rilimogene glafolivec, or “rilimogene”) in treatment of metastatic, castration-resistant prostate cancer (mCRPC) are now expected in the second half of 2017. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, mCRPC, metastatic, Prostvac, rilimogene | 9 Comments »
Posted on January 2, 2017 by Sitemaster
The Society for Immunotherapy of Cancer has just issued a detailed statement on the role of immunotherapy in the management of prostate cancer. The full text of this article by McNeel et al. is available on line. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: guidelines, immunotherapy, Prostvac, Provenge, sipuleucel-T | 3 Comments »
Posted on August 1, 2016 by Sitemaster
The Phase III clinical trial of Prostvac VF (rilimogene galvacirepvec/rilimogene glafolivec) in treatment of metastatic, castration-resistant prostate cancer is now fully enrolled, and initial results of this critical trial are expected within the next 12 months. However, … READ MORE …
Filed under: Drugs in development | Tagged: Prostvac, rilimogene | 5 Comments »
Posted on August 3, 2015 by Sitemaster
If readers come across a report this week suggesting that Barvarian Nordic’s Prostvac VF is likely to fail in the demonstration of effectiveness in its ongoing Phase III trial, you might want to treat that report with some caution. … READ MORE …
Filed under: Drugs in development | Tagged: Barvarian Nordic, manipulation, Prostvac, stock | 1 Comment »
Posted on July 24, 2015 by Sitemaster
There appears to be a high degree of confidence that Barvarian Nordic’s Prostvac will show positive results in the ongoing Phase III clinical trial in men with metastatic, castration-resistant prostate cancer. An early stage trial has now been initiated among men with much less advanced disease disease. … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: active surveillance, immunotherapy, Prostvac, trial | 5 Comments »
Posted on March 4, 2015 by Sitemaster
According to a Reuters report issued early this morning, the CEO of Barvarian Nordic has stated publicly that the company expects results of Phase III trials of Prostvac VF in men with metastatic, castration-resistant prostate cancer (mCRPC) by early 2017 or perhaps earlier. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: Barvarian Nordic, castration-resistant, mCRPC, metastatic, Prostvac | 3 Comments »
Posted on February 26, 2015 by Sitemaster
Results from a small trial of Barvarian Nordic’s investigational drug Prostvac — used in combination with Bristol-Myers Squibb’s ipilimumab (Yervoy) — appear to have shown relatively dramatic effects in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, ipilimumab, mCRPC, metastatic, Prostvac, Yervoy | 6 Comments »
Posted on December 22, 2014 by Sitemaster
A study just published in European Urology has suggested that early therapy with Prostvac-type vaccines might have value in the management of men with a rising PSA after first-line therapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: progressive, Prostvac, PSA, rising, vaccine | 2 Comments »
Posted on April 16, 2012 by Sitemaster
According to a story in the UK’s Daily Telegraph this morning, the British government has given approval for eligible patients in the UK to participate in the randomized, Phase III trial of Prostvac VF — a new form of immunotherapy being tested in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, mCRPC, metastatic, Prostvac, UK | Leave a comment »
Posted on February 23, 2012 by Sitemaster
A media release issued earlier today by Barvarian Nordic (the developer of Prostvac®) gives us an inkling of where we may be headed in the development of combination therapies for the management of late stage (and maybe even earlier stage) forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castrate-resistant, combination, immunotherapeutic, ipilimumab, mCRPC, outcome, Prostvac, survival | Leave a comment »
Posted on November 15, 2011 by Sitemaster
Barvarian Nordic has initiated the expected, randomized, multi-center Phase III trial of Prostvac® in men with asymptomatic and minimally symptomatic, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: mCRPC, Phase III, Prostvac, trial | 6 Comments »
Posted on March 3, 2011 by Sitemaster
According to a media release from Bavarian Nordic, issued on Monday, the company has initiated a new, randomized, multi-center, Phase II clinical trial of its investigational immunotherapeutic agent, Prostvac®, in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: castration-resistant, mCRPC, metastatic, Prostvac | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 